N/A N=241 Automated Graduated CPAP (AGPAP) for Improved Adherence in Newly Diagnosed Obstructive Sleep Apnea (OSA) Patients
Obstructive Sleep Apnea
Primary: CPAP Adherence — 3.6; 4.0 hours per night
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 IBUPAP Study for Pain Management in Children
Pain Management
Primary: Pain Score at 60 Minutes — 2.72; 3.10; 2.77 units on a scale
N/A N=40 Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
Phase 4 N=131 Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
N/A N=460 Cerebral Autoregulation Monitoring During Cardiac Surgery
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Phase 1 N=9 Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
Acute Myeloid Leukemia
Primary: Incidence of Relapse of Acute Myeloid Leukemia Based on the International Working Group Response Criteria — 2; 2; 2 participants
N/A N=10 Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials
Alzheimer Disease
Primary: Percentage of Adherence to Daily Device Use — 95.55; 95.37 percentage of adherence to treatment
Phase 3 N=121 Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Hereditary Angioedema · HAE
Primary: Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) — 1.65; 1.31; 2.35 HAE attack rate per 28…
N/A N=128 Stimgenics Open-Label, Post Market Study
Chronic Low Back Pain
Primary: The Percentage of Individual Responders — 80.9; 50.9 percentage of responders
N/A N=33 Development and Validation of the Client Centered Occupational Therapy Service Model
Occupational Therapy · Psychiatric Rehabilitation
Primary: Occupational Performance History Interview-II (OPHI-II) Total and Subscale Scores — 66.2; 69.4; 24.9; 25.7 score on a scale — p=<0.001
Phase 2 N=96 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Squamous Cell Carcinoma of the Head and Neck · Carcinoma, Squamous Cell of the Head and Neck · Cancer of Head and Neck
Primary: Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site — 28; 8 Participants
N/A N=115 Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Average Dose of Inflectra at Visit 1 — 457.28; 585.71; 579.44; 449.76 milligram
Phase 3 N=250 Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
Digestive System Disease
Primary: Percentage of Subjects With Successful Overall Colon Preparation, Assessed With the Cleansing Score (4-point Scale) — 71.42; 79.03 adjusted percentage of subjects…
Phase 3 N=22 Nabilone for Non-motor Symptoms in Parkinson's Disease
Parkinson Disease
Primary: AEs in PD Patients Taking Nabilone, Between V 1 and V 3 — 39 adverse events
Phase 2 N=47 Nabilone for Non-motor Symptoms in Parkinson's Disease
Parkinson Disease
Primary: Changes of Non-motor Symptoms — 1.00; 2.63 units on a scale